Pathological features and clinical results of eosinophilic and non-eosinophilic CRSwNP
A total of 47.22% of patients were classified with eosinophilic CRSwNP in our study. For general VAS score in eosinophilic CRSwNP patients, the decrease in the rh-bFGF nasal-drop group was more obvious than that in the control group at 2 weeks (P3=0.005), 1 month(P3=0.04),6 months(P3=0.001) and 1 year(P3=0.04,Figure5A-D). The decrease in general VAS scores in the rh-bFGF nasal-spray group was more obvious than in the control group. However, statistical difference was only found at 6 months between nasal-spray and control group(P2=0.004,Figure5C). For non-eosinophilic CRSwNP patients, no significant difference was found among the three group after ESS, except for nasal-drop group at 1year(FigureS3A-D).
For SNOT-22 scores in eosinophilic CRSwNP patients, the reduction in rh-bFGF nasal experimental groups was greater than in control group. However, no significant difference was found(Figure5E-H). For non-eosinophilic CRSwNP patients, significant difference was only found between nasal-drop and control group at 2 weeks (P1=0.15,P3=0.04,FigureS3E). 1 month and 1 year after ESS, the SNOT-22 scores of nasal-spray was significant lower than that of control group(P1=0.04,FigureS3F,H). As for other postoperative time points, there was no significant difference in SNOT-22 score among the three groups(FigureS3F-H).
For L-K score of eosinophilic CRSwNP patients, the reduction in the rh-bFGF nasal-spray group was more obvious than that of the control group at both 2 weeks (P1=0.02) and 1 month(P1=0.01,Figure5E,F). Moreover, a significant difference was found between the control and rh-bFGF nasal-drop groups at 1 month(P3=0.01), 6 months(P3=0.04) and 1 year(P3=0.01), but no significant difference was observed at 2 weeks(P3=0.43,Figure5E-H). However, for non-eosinophilic CRSwNP patients, only L-K score of nasal-drop group was significant lower than control group at 1 month(P3=0.04, FigureS3I-L).